Quick Search
  Home Journal Information Current Issue Past Issues Services Contact Us  
Articles
Early recombinant human growth hormone treatment improves mental development and alleviates deterioration of motor function in infants and young children with Prader每Willi syndrome 
 
Early recombinant human growth hormone treatment improves mental development and alleviates deterioration of motor function in infants and young children with Prader每Willi syndrome
  Ruo-Qian Cheng, Yan-Qin Ying, Zheng-Qing Qiu, Jun-Fen Fu, Chun-Xiu Gong, Yan-Ling Yang, Wei Shi, Hui Li, Ming-Sheng Ma, Chang-Yan Wang, Min Liu, Jia-Jia Chen, Chang Su, Xiao-Ping Luo, Fei-Hong Luo, Wei Lu
 [Abstract] [Full Text] [PDF]   Pageviews: 1326 Times
 
Background: Recombinant human growth hormone (rhGH) therapy has shown to improve height and body composition in children with Prader每Willi syndrome (PWS), the evidence of early rhGH treatment on motor and mental development is still accumulating. This study explored the time effect on psychomotor development, anthropometric indexes, and safety for infants and young children with PWS.
Methods: A phase 3, single-arm, multicenter, self-controlled study was conducted in six sites. Patients received rhGH at 0.5 mg/m2/day for first four weeks, and 1 mg/m2/day thereafter for up to 52 weeks. Motor development was measured using Peabody Developmental Motor Scales-second edition, mental development using Griffiths Development Scales-Chinese (GDS-C). Height standard deviation score (SDS), body weight SDS, and body mass index (BMI) SDS were also assessed.
Results: Thirty-five patients were enrolled totally. Significant improvements were observed in height, body weight, and BMI SDS at week 52; GDS-C score showed significant improvement in general quotient (GQ) and sub-quotients. In a linear regression analysis, total motor quotient (TMQ), gross motor quotient (GMQ), and fi ne motor quotient were negatively correlated with age; however, treatment may attenuate deterioration of TMQ and GMQ. Changes in GQ and locomotor sub-quotient in < 9-month group were signifi cantly higher than ≡ 9-month group. Mild to moderate severity adverse drug reactions were reported in six patients.
Conclusion: Fifty-two-week treatment with rhGH improved growth, BMI, mental development, and lessened the deterioration of motor function in infants and young children with PWS. Improved mental development was more pronounced when instituted in patients < 9 months old.
 
  [Articles Comment]

  title Author The End Revert Time Revert / Count

  Username:
  Comment Title: 
 
   

 

     
 
     
World Journal of Pediatric Surgery

roger vivier bags 美女 美女

Home  |  Journal Information  |  Current Issue  |  Past Issues  |  Journal Information  |  Contact Us
Children's Hospital, Zhejiang University School of Medicine, China
Copyright 2007  www.wjpch.com  All Rights Reserved Designed by eb